Envoy Medical Secures Four New Global Patents, Expanding Its Leadership Position in Fully Implantable Hearing Technology

Patents strengthen Envoy Medical's innovation pipeline and protect next-generation cochlear implant solutions for individuals living with hearing loss.

White Bear Lake, Minnesota--(Newsfile Corp. - September 9, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced the issuance of four new global patents. These patents expand the company's global intellectual property portfolio and mark another strategic step in delivering next-generation cochlear implant solutions that offer patients discreet, 24/7 hearing experience without the limitation of externally worn components.

The following patents are being issued to Envoy Medical:

• U.S. Patent No. 12,418,758 on September 16, 2025. The title is Programming of Cochlear Implant Accessories. This patent will relate to systems and methods for easily communicating with, charging, and pairing multiple cochlear implant accessory devices.

• Australian Patent No. 2020224666, on August 7, 2025. The title is Implantable Cochlear System with Integrated Components and Lead Characterization. This patent relates to characterizing conductors between components of a cochlear implant system by grounding one conductor and applying a test signal to a different conductor.

• Australian Patent No. 2021334336 on July 31, 2025. The title is Programming of Cochlear Implant Accessories. This patent relates to systems and methods for easily communicating with and pairing accessory devices to a cochlear implant system.

• Australian Patent No. 2022227536 on July 24, 2025. The title is Cochlear Implant System with Integrated Signal Analysis Functionality. This patent relates to using an external device to designate a signal within a fully implantable cochlear implant system for analysis and to receive a representative signal from the cochlear implant system.

"These four new patents represent yet another important step in strengthening our global intellectual property portfolio and reinforcing our position at the forefront of fully implanted hearing solutions," said Brent Lucas, Chief Executive Officer of Envoy Medical. "The granted patents cover critical technologies to support improvements in how our cochlear implant device is programmed and maintained, aligning with our mission to deliver discreet, intuitive, and life-changing hearing experiences. As we continue to develop and protect innovations that eliminate the burdens of external wearable hardware, we are proud to be another step closer to bringing transformative hearing solutions to more patients around the world."

For more information about Envoy Medical's innovation pipeline and intellectual property portfolio, visit www.envoymedical.com.

To be added to the Envoy Medical email distribution list, please email Envoy@kcsa.com with COCH in the subject line.

About Envoy Medical, Inc.

Envoy Medical (NASDAQ: COCH) is a hearing health company focused on providing innovative technologies across the hearing loss spectrum. Envoy Medical has pioneered one-of-a-kind, fully implanted devices for hearing loss, including its fully implanted Esteem® active middle ear implant, commercially available in the U.S. since 2010, and the fully implanted Acclaim® cochlear implant, an investigational device. Envoy Medical is dedicated to pushing hearing technology beyond the status quo to improve access, usability, compliance, and ultimately quality of life.

About the Fully Implanted Acclaim® Cochlear Implant

We believe the fully implanted Acclaim Cochlear Implant ("Acclaim CI") is a first-of-its-kind hearing device. Envoy Medical's fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound.

The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician.

The Acclaim Cochlear Implant received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019.

CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.

About the Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI)

The Esteem fully implanted active middle ear implant (FI-AMEI) is the only FDA-approved, fully implanted* hearing device for adults diagnosed with moderate to severe sensorineural hearing loss allowing for 24/7 hearing capability using the ear's natural anatomy. The Esteem FI-AMEI hearing implant is invisible and requires no externally worn components and nothing is placed in the ear canal for it to function. Unlike hearing aids, you never put it on or take it off. You can't lose it. You don't clean it. The Esteem FI-AMEI hearing implant offers true 24/7 hearing.

*Once activated, the external Esteem FI-AMEI Personal Programmer is not required for daily use.

Important safety information for the Esteem FI-AMEI can be found at: https://www.envoymedical.com/safety-information.

Additional Information and Where to Find It

Copies of the documents filed by Envoy Medical with the SEC may be obtained free of charge at the SEC's website at www.sec.gov.

See important information here: https://landing.envoymedical.com/important-information